-
2023-509605-77-00
1
2019-06-27
Advanced solid tumours
-
2023-510268-11-00
4
2019-06-11
Cervical cancer
-
2023-508681-15-00
4
2019-05-28
Adult focal (partial onset) epilepsy
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-509059-15-00
7
2019-04-30
Malignant solid tumors: endometrial carcinoma (EC), urothelial carcino
-
2024-519288-17-00
4
2019-04-26
High-risk Non-muscle Invasive Bladder Cancer
-
2024-512667-31-00
5
2019-04-23
Main cohort: Patients with unresected Stage I/II, lymph-node negative
-
2023-508864-31-00
5
2019-04-03
Achondroplasia
-
2024-510985-17-00
4
2019-03-14
First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive
-
2023-507564-39-00
1
2019-03-11
Patients with Advanced Solid Tumors
-
2023-503254-12-00
5
2019-03-06
Metastatic Prostate Cancer
-
2023-509576-42-00
5
2019-02-21
Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
-
2024-513867-19-00
5
2019-01-31
metastatic Castration-Resistant Prostate Cancer (mCRPC)
-
2023-507906-15-00
5
2019-01-30
Relapsing multiple sclerosis (RMS)
-
2023-506777-36-00
10
2019-01-04
Prostate Cancer
-
2024-511648-16-00
5
2019-01-04
Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresecta
-
2022-501485-22-00
5
2018-12-18
Myelodysplastic syndrome (MDS)
-
2024-510976-19-00
5
2018-11-30
Patients with Unresectable Locally Advanced or Metastatic Urothelial C
-
2024-516905-22-00
5
2018-10-22
Multiple myeloma
-
2024-510967-41-00
5
2018-09-21
Metastatic colorectal cancer
-
2022-500860-36-00
5
2018-09-19
Histologically documented non-small cell lung cancer of predominantly
-
2024-513206-65-00
5
2018-08-10
resected squamous cell carcinoma of head and neck
-
2023-505341-23-00
5
2018-07-27
Non-muscle invasive bladder cancer
-
2023-505222-34-00
7
2018-04-23
Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)